Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Perspectives on Manufacturing of High-Quality Cell Therapies.

Literature DB >> 28462818

Perspectives on Manufacturing of High-Quality Cell Therapies.

Isabelle Rivière¹, Krishnendu Roy².

Abstract

Mesh：

Substances：
Adenosine Deaminase

Year: 2017 PMID： 28462818 PMCID： PMC5417835 DOI： 10.1016/j.ymthe.2017.04.010

Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454

× No keyword cloud information.

13 in total

Review 1. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Authors: X Wang; I Rivière
Journal: Cancer Gene Ther Date: 2015-02-27 Impact factor: 5.987

2. Achieving Efficient Manufacturing and Quality Assurance through Synthetic Cell Therapy Design.

Authors: Yonatan Y Lipsitz; Patrick Bedford; Anthony H Davies; Nicholas E Timmins; Peter W Zandstra
Journal: Cell Stem Cell Date: 2017-01-05 Impact factor: 24.633

Review 3. Biomanufacturing of Therapeutic Cells: State of the Art, Current Challenges, and Future Perspectives.

Authors: Kyung-Ho Roh; Robert M Nerem; Krishnendu Roy
Journal: Annu Rev Chem Biomol Eng Date: 2016-06-07 Impact factor: 11.059

4. ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.

Authors: Seppo Ylä-Herttuala
Journal: Mol Ther Date: 2016-06 Impact factor: 11.454

Review 5. Commercialization of cellular immunotherapies for cancer.

Authors: Anthony Walker; Robert Johnson
Journal: Biochem Soc Trans Date: 2016-04-15 Impact factor: 5.407

6. Morphological features of IFN-γ-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity.

Authors: Matthew W Klinker; Ross A Marklein; Jessica L Lo Surdo; Cheng-Hong Wei; Steven R Bauer
Journal: Proc Natl Acad Sci U S A Date: 2017-03-10 Impact factor: 11.205

Review 7. CAR therapy: the CD19 paradigm.

Authors: Michel Sadelain
Journal: J Clin Invest Date: 2015-09-01 Impact factor: 14.808

Review 8. Towards a commercial process for the manufacture of genetically modified T cells for therapy.

Authors: A D Kaiser; M Assenmacher; B Schröder; M Meyer; R Orentas; U Bethke; B Dropulic
Journal: Cancer Gene Ther Date: 2015-01-23 Impact factor: 5.987

Review 9. Genetic Engineering and Manufacturing of Hematopoietic Stem Cells.

Authors: Xiuyan Wang; Isabelle Rivière
Journal: Mol Ther Methods Clin Dev Date: 2017-03-18 Impact factor: 6.698

Review 10. Clinical manufacturing of CAR T cells: foundation of a promising therapy.

Authors: Xiuyan Wang; Isabelle Rivière
Journal: Mol Ther Oncolytics Date: 2016-06-15 Impact factor: 7.200

6 in total

1. Functional imaging with dynamic quantitative oblique back-illumination microscopy.

Authors: Paloma Casteleiro Costa; Bryan Wang; Caroline Filan; Annie Bowles-Welch; Carolyn Yeago; Krishnendu Roy; Francisco E Robles
Journal: J Biomed Opt Date: 2022-06 Impact factor: 3.758

Review 2. Promises and challenges of adoptive T-cell therapies for solid tumours.

Authors: Matteo Morotti; Ashwag Albukhari; Abdulkhaliq Alsaadi; Mara Artibani; James D Brenton; Stuart M Curbishley; Tao Dong; Michael L Dustin; Zhiyuan Hu; Nicholas McGranahan; Martin L Miller; Laura Santana-Gonzalez; Leonard W Seymour; Tingyan Shi; Peter Van Loo; Christopher Yau; Helen White; Nina Wietek; David N Church; David C Wedge; Ahmed A Ahmed
Journal: Br J Cancer Date: 2021-03-29 Impact factor: 7.640

3. Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway.

Authors: Jisun Lim; Jinbeom Heo; Hyein Ju; Ji-Woong Shin; YongHwan Kim; Seungun Lee; Hwan Yeul Yu; Chae-Min Ryu; HongDuck Yun; Sujin Song; Ki-Sung Hong; Hyung-Min Chung; Hwa-Ryeon Kim; Jae-Seok Roe; Kihang Choi; In-Gyu Kim; Eui Man Jeong; Dong-Myung Shin
Journal: Sci Adv Date: 2020-04-15 Impact factor: 14.136